Trevor Allred
Stock Analyst at Oppenheimer
(4.73)
# 123
Out of 5,182 analysts
19
Total ratings
88.89%
Success rate
48.22%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trevor Allred
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TBPH Theravance Biopharma | Downgrades: Perform | n/a | $16.76 | - | 2 | Mar 5, 2026 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $275 → $277 | $232.32 | +19.23% | 9 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $83 → $81 | $69.71 | +16.20% | 2 | Feb 25, 2026 | |
| LEGN Legend Biotech | Initiates: Outperform | $75 | $23.56 | +218.34% | 1 | Jan 7, 2026 | |
| DSGN Design Therapeutics | Initiates: Outperform | $18 | $12.81 | +40.52% | 1 | Jan 7, 2026 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $80 | $29.04 | +175.48% | 2 | Sep 23, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $85 | $125.96 | -32.52% | 1 | Sep 9, 2025 | |
| INVA Innoviva | Initiates: Outperform | $35 | $23.69 | +47.74% | 1 | Aug 11, 2025 |
Theravance Biopharma
Mar 5, 2026
Downgrades: Perform
Price Target: n/a
Current: $16.76
Upside: -
Ligand Pharmaceuticals
Feb 27, 2026
Maintains: Outperform
Price Target: $275 → $277
Current: $232.32
Upside: +19.23%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $83 → $81
Current: $69.71
Upside: +16.20%
Legend Biotech
Jan 7, 2026
Initiates: Outperform
Price Target: $75
Current: $23.56
Upside: +218.34%
Design Therapeutics
Jan 7, 2026
Initiates: Outperform
Price Target: $18
Current: $12.81
Upside: +40.52%
MBX Biosciences
Sep 23, 2025
Maintains: Outperform
Price Target: $38 → $80
Current: $29.04
Upside: +175.48%
Palvella Therapeutics
Sep 9, 2025
Initiates: Outperform
Price Target: $85
Current: $125.96
Upside: -32.52%
Innoviva
Aug 11, 2025
Initiates: Outperform
Price Target: $35
Current: $23.69
Upside: +47.74%